Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MUTATIONAL STATUS AND TREATMENT EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.

Problemy radiatsiinoi medytsyny ta radiobiolohii - 1 Dec 2025

Dyagil I S, Bazyka D A, Kirieieva I V, Panchenko V V, Zvarich L M, Syvak L A, Sholoiko V V

Abstract excerpt

BACKGROUND: The use of targeted therapy for chronic myeloid leukemia (CML) - tyrosine kinase inhibitors (TKIs) - has led to significant success in the treatment of patients with CML. The life expectancy of patients with newly diagnosed CML is almost equal to that of the general population. A significant proportion of patients on TKI therapy achieve stable and long'term remission, and after two or more years, it...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Molecular Targeted Therapy

Share to Mutation

Share to Treatment Outcome

Share to Tyrosine Kinase Inhibitors

Source

Identifiers

PMID: 41469338
DOI: 10.33145/2304-8336-2025-30-18-31

Genes

BCR
ABL1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MUTATIONAL STATUS AND TREATMENT EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.PMID 41469338Read ↗

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.Semantic proximity Read ↗

ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.Semantic proximity Read ↗

BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.Semantic proximity Read ↗

A review of the European LeukemiaNet recommendations for the management of CML.Semantic proximity Read ↗

Mutation Profiling of BCR-ABL Kinase Domain in Chronic Myeloid Leukaemia Patients with Imatinib ResistanceSemantic proximity Read ↗

Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and managementSemantic proximity Read ↗

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapySemantic proximity Read ↗

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and managementSemantic proximity Read ↗

Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoringSemantic proximity Read ↗

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoringSemantic proximity Read ↗

Mutations in the BCR‑ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosisSemantic proximity Read ↗

Clinical characteristics, disease evolution and survival in patients with chronic myeloid leukemia, BCR-ABL1 (+) and T315I mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.